Physician profile
Robin Mclinn
NPI 1033725817
$5,371.11
in general payments reported to CMS, 2019-2025
21 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $550 · 2023: $1,182 · 2024: $2,221 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,298 · Food and Beverage: $1,381 · Education: $519 · Consulting Fee: $325 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,297.62 |
| Food and Beverage | $1,380.59 |
| Education | $518.77 |
| Consulting Fee | $325.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $1,597.62 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $776.84 | 2025 | |
| Novartis Pharmaceuticals Corporation | $398.80 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $394.97 | 2022-2024 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $304.20 | 2022-2025 | Erleada, Imbruvica, Darzalex |
| Stemline Therapeutics INC. | $257.44 | 2023-2024 | Orserdu |
| Alexion Pharmaceuticals, INC. | $250.00 | 2025 | Ultomiris |
| Sobi, INC | $246.68 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $210.25 | 2024-2025 | Lynparza, Enhertu, Imfinzi |
| Sanofi-Aventis U.S. LLC | $171.95 | 2023-2024 | |
| Abbott Laboratories | $148.57 | 2022 | |
| Janssen Scientific Affairs, LLC | $121.35 | 2023 | Erleada |
| Lilly USA, LLC | $105.62 | 2023 | Retevmo, Jaypirca |
| Incyte Corporation | $102.97 | 2022 | |
| Cardinal Health 110 LLC | $75.00 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $53.84 | 2022 | |
| Adaptive Biotechnologies Corporation | $49.81 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $34.73 | 2024-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $32.87 | 2025 | |
| Beone Medicines USA, INC. | $21.25 | 2025 | Tevimbra |
| Nuvation Bio INC. | $16.35 | 2025 | Ibtrozi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Mclinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.